Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Br J Ophthalmol

Retrieve available abstracts of 6 articles:
HTML format

Single Articles

    January 2021
  1. SINGH L, Singh MK, Rizvi MA, Pushker N, et al
    Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Br J Ophthalmol. 2021;105:48-56.
    PubMed     Abstract available

    October 2020
  2. VAN IPENBURG JA, Naus NC, Dubbink HJ, van Ginderdeuren R, et al
    Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features.
    Br J Ophthalmol. 2020 Oct 30. pii: bjophthalmol-2020-317405.
    PubMed     Abstract available

    July 2020
  3. HOLM F, Mikkelsen LH, Kamper P, Rasmussen PK, et al
    Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017.
    Br J Ophthalmol. 2020 Jul 30. pii: bjophthalmol-2019-315637.
    PubMed     Abstract available

    April 2020
  4. KWON M, Lee JS, Lee C, Yoon DH, et al
    Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification.
    Br J Ophthalmol. 2020 Apr 23. pii: bjophthalmol-2020-315875.
    PubMed     Abstract available

    July 2019
  5. WANG L, Ding L, Liu Z, Sun L, et al
    Automated identification of malignancy in whole-slide pathological images: identification of eyelid malignant melanoma in gigapixel pathological slides using deep learning.
    Br J Ophthalmol. 2019 Jul 13. pii: bjophthalmol-2018-313706.
    PubMed     Abstract available

    April 2019
  6. BHARDWAJ M, Sen S, Chosdol K, Bakhshi S, et al
    Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma.
    Br J Ophthalmol. 2019 Apr 2. pii: bjophthalmol-2018-313285.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.